Patient & Family Webinar: From Best of ASH 2021 to 2022 COVID-19 Guidance

Patient & Family Webinar: From Best of ASH 2021 to 2022 COVID-19 Guidance

Share This Content
Learn how to better manage side effects, discover optimal choices for relapsed patients, receive updates on ASH 2021 and 2022 COVID-19 Guidance, gather information about CAR T-cell therapies, and more. IMF Chairman of the Board Dr. Brian G.M. Durie moderates presentations by Dr. Thomas Martin (University of California — San Francisco, CA), Dr. Saad Usmani (Memorial Sloan Kettering Cancer Center — New York, NY), and Donna Catamero, ANP-BC, OCN, CCRC of the IMF Nurse Leadership Board (Ichan School of Medicine at Mount Sinai Hospital — New York, NY).

What to Expect

0:00:06 IMF Nurse Leadership Board Member Donna Catamero ANP-BC, OCN, CCRC (Mount Sinai Health System, IMF Nurse Leadership Board) will present Side Effects and Symptom Management and discuss how patients can best manage myeloma-related symptoms and side effects, as well as side effects brought on by treatment. She outlines the most common side effects for each myeloma drug category, and more.

0:37:51 Dr. Durie follows with a review of Myeloma 101. He will discuss MGUS, smoldering myeloma, and active myeloma, and address when patients may consider beginning treatment. He will also cover tests for diagnosis and monitoring, as well as how the disease is staged, and more.

1:14:22 In his segment, Best of ASH 2021 to 2022 COVID-19 Guidance, Dr. Durie will share updates from the top myeloma-related abstracts from the 2021 American Society of Hematology (ASH) meeting and provide the latest COVID-19 guidance and recommendations for patients in 2022.

1:50:26 In this presentation on the Evolving Role of Immune Therapies: A Focus on CAR T-cell Therapies, Dr. Thomas Martin (University of California — San Francisco) will discuss the remarkable progress being made in the treatment of multiple myeloma using immune therapies, with a specific focus on CAR T-cell therapies. He will detail what CAR T-cell therapy is and how this type of therapy uses a patient's own immune system to target myeloma. Dr. Martin will also outline other emerging immune therapies on the horizon.

2:24:15 Saad Usmani, MD (Memorial Sloan Kettering Cancer Center) will talk about Approaches to Relapse. He will cover how patients should treat relapsed disease, the current bispecifics and novel agents available, and practical approaches to relapse.

Improving Lives | Finding the Cure

In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel:

Visit our website at:

Find us online:
Facebook: @myeloma |
Twitter: @IMFMyeloma |
Instagram: @imfmyeloma |

Support the IMF!
Nonprofits & Activism
Standard YouTube License

In most cases, captions are autogenerated by YouTube.